Join InvestorPlace Insights — FREE!
Get actionable advice from our top experts, including the hottest stocks to buy & sell, 401k and retirement tips, market analysis and more!
CTRM stock is incredibly overvalued compared to its peers and is unattractive without a major price correction
GNUS stock has a promising content lineup this year and has plenty of cash in hand with zero debt to invest in its business
Despite releasing Truforma ahead of schedule, Zomedica still has to overcome tough challenges facing the product. Investors should not buy ZOM stock yet.